WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532049

CAS#: 214348-67-1

Description: L-054,522 is potent, selective somatostatin receptor agonists.

Price and Availability




L-054,522 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 532049
Name: L-054,522
CAS#: 214348-67-1
Chemical Formula: C35H47N7O5
Exact Mass: 645.3639
Molecular Weight: 645.81
Elemental Analysis: C, 65.09; H, 7.34; N, 15.18; O, 12.39

Synonym: L-054,522; L 054,522; L054,522.

IUPAC/Chemical Name: tert-butyl (2S)-6-amino-2-[[(2R,3S)-3-(1H-indol-3-yl)-2-[[4-(2-oxo-3H-benzimidazol-1-yl)piperidine-1-carbonyl]amino]butanoyl]amino]hexanoate


InChi Code: InChI=1S/C35H47N7O5/c1-22(25-21-37-26-12-6-5-11-24(25)26)30(31(43)38-28(14-9-10-18-36)32(44)47-35(2,3)4)40-33(45)41-19-16-23(17-20-41)42-29-15-8-7-13-27(29)39-34(42)46/h5-8,11-13,15,21-23,28,30,37H,9-10,14,16-20,36H2,1-4H3,(H,38,43)(H,39,46)(H,40,45)/t22-,28-,30+/m0/s1


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Stark A, Mentlein R. Somatostatin inhibits glucagon-like peptide-1-induced insulin secretion and proliferation of RINm5F insulinoma cells. Regul Pept. 2002 Oct 15;108(2-3):97-102. PubMed PMID: 12220732.

2: Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int J Cancer. 2001 May 15;92(4):545-50. PubMed PMID: 11304689.

3: Held-Feindt J, Forstreuter F, Pufe T, Mentlein R. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res Mol Brain Res. 2001 Feb 19;87(1):12-21. PubMed PMID: 11223155.

4: Rohrer SP, Schaeffer JM. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol Paris. 2000 May-Aug;94(3-4):211-5. PubMed PMID: 11087999.

5: Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, Birzin ET, Huskey SE, Jacks T, Schleim KD, Cheng K, Schaeffer JM, Patchett AA, Yang L. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett. 1999 Feb 8;9(3):491-6. PubMed PMID: 10091708.

6: Yang L, Berk SC, Rohrer SP, Mosley RT, Guo L, Underwood DJ, Arison BH, Birzin ET, Hayes EC, Mitra SW, Parmar RM, Cheng K, Wu TJ, Butler BS, Foor F, Pasternak A, Pan Y, Silva M, Freidinger RM, Smith RG, Chapman K, Schaeffer JM, Patchett AA. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. PubMed PMID: 9724791; PubMed Central PMCID: PMC27982.